An update from TELA Bio ( (TELA) ) is now available.
On May 8, 2025, TELA Bio reported its financial results for the first quarter of 2025, showing a revenue increase to $18.5 million, up 12% from the previous year. The growth was driven by increased demand for their OviTex products and the full U.S. commercial launch of larger-sized OviTex PRS. Despite the revenue growth, the company reported a net loss of $11.3 million, attributed to decreased gross margins and increased operating expenses. TELA Bio reiterated its full-year revenue guidance, expecting a 23% to 27% growth over 2024, and highlighted the optimization of its sales organization as a key factor in achieving new account wins and market penetration.
Spark’s Take on TELA Stock
According to Spark, TipRanks’ AI Analyst, TELA is a Neutral.
TELA Bio’s stock score reflects strong revenue growth and a stable financial structure, but is weighed down by ongoing profitability challenges and bearish technical indicators. Positive projections from the earnings call offer some optimism, but the company must address operational and sales force issues to improve its market position.
To see Spark’s full report on TELA stock, click here.
More about TELA Bio
TELA Bio, Inc. is a commercial-stage medical technology company that focuses on innovative soft-tissue reconstruction solutions. The company aims to optimize clinical outcomes by preserving and restoring patients’ own anatomy, providing advanced and economically effective solutions that leverage natural healing responses while minimizing exposure to synthetic materials.
Average Trading Volume: 255,500
Technical Sentiment Signal: Sell
Current Market Cap: $38.17M
See more insights into TELA stock on TipRanks’ Stock Analysis page.